Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.
Neoadjuvant atezolizumab as a treatment for muscle-invasive urothelial cancer of the bladder yielded a high disease-free survival.
Based on the results of the AZA-JMML-001 trial, the FDA has approved azacitidine for use in newly diagnosed juvenile myelomonocytic leukemia.
Patients with advanced renal cell carcinoma who were treated with lenvatinib plus pembrolizumab had health-related quality of life comparable with sunitinib.
Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer may receive alternative treatment with switch maintenance endocrine therapy and bevacizumab and experience notable efficacy and improved safety vs continued weekly paclitaxel and bevacizumab.
A panel of experts provides a discussion on treatments for newly diagnosed transplant-eligible and transplant-ineligible relapsed multiple myeloma, and how recent clinical trial data presented at ASH 2021 can be applied to clinical practice.
Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.
A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.
Updated results from the phase 3 IKEMA study showed a progression-free survival benefit with the addition of isatuximab to carfilzomib and dexamethasone that was consistent with interim results in patients with relapsed multiple myeloma.
Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.